GC-022 is under clinical development by Gracell Biotechnologies and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GC-022’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GC-022 overview
GC-022 is under development for the treatment of pediatric and adults relapsed/refractory B-cell acute lymphoblastic leukemia, transformed follicular lymphoma (TFL) and mantle cell lymphoma (MCL). The therapeutic candidate constitutes T cells modified to express chimeric antigen receptors (CAR) targeting tumor cells expressing CD19 and CD22. It is administered through infusion.
It was also under development for the treatment of diffuse large B cell lymphoma (DLBCL) and primary mediastinal B cell lymphoma (PMBCL).
Gracell Biotechnologies overview
Gracell Biotechnology Shanghai Co Ltd operates as a biopharmaceutical company. The Company develops cellular therapeutics and other biotechnology. The company is headquartered in China.
For a complete picture of GC-022’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
